University of Leicester researcher in potential medical breakthrough
“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.
People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”
Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.
The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.
“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”
After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.
Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.
Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.
Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.
The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals – focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
The Latest on: Asthma pill
via Google News
The Latest on: Asthma pill
- FDA approves Teva's digital inhaler for asthma & COPD patients on December 27, 2018 at 10:26 am
“One of the challenges physicians are faced with in caring for their asthma and COPD patients is knowing if their patients are using their inhaled medication as they should," said Dr. Tushar Shah, glo... […]
- FDA OKs mHealth Device, App for Asthma, COPD Care Management on December 26, 2018 at 7:05 am
“One of the challenges physicians are faced with in caring for their asthma and COPD patients is knowing if their patients are using their inhaled medication as they should. That’s what makes a produc... […]
- Asthma Spacers Market to Reach US $1,803.93 Mn by the End of 2026 on December 24, 2018 at 7:37 am
While using asthma spacers, the velocity at which the medication leaves the MDI (estimated at 60mph) is slowed down substantially. It also allows the propellant to evaporate, leaving only the smaller ... […]
- MEDICAL MATTERS: Exercise Induced Asthma - A Seasonal Condition? on December 23, 2018 at 2:30 am
Your health care provider can help you find the best treatment program for you based on your asthma history and the type of activity. Short-acting beta agonist / bronchodilator This medication can pre... […]
- Monroe Regional Hospital adds pulmonary, sleep medicine doctor on December 21, 2018 at 5:59 am
“I grew up across the street from my grandfather, and he was a physician who practiced family medicine in Eutaw, Alabama. I always wanted to do it,” he said of his career aspirations. Primary symptoms ... […]
- Being overweight or obese may account for 10 percent of children’s asthma cases on December 20, 2018 at 8:53 am
Pediatric asthma is one of the most widespread childhood conditions ... Kate Cronan, MD, is a pediatric emergency medicine physician at Nemours/Alfred I. duPont Hospital for Children. (c)2018 Philly.c... […]
- Homeopathy for Asthma on December 17, 2018 at 10:27 am
They believe these will help the body to heal itself. In homeopathic medicine, the goal is to treat asthma with a minimal dose that can result in symptoms similar to asthma. This triggers the body’s n... […]
- Teen’s asthma frames town’s struggle with dirty air on December 15, 2018 at 9:10 am
He’s 13. And the sixth grader has persistent asthma. He takes four medications daily — a regimen of inhalers and nebulizers and pills to calm the inflammation that can make it hard for him to catch hi... […]
- Rate of Asthma Cases in Haifa's Children More Than Double Israeli Average on December 14, 2018 at 9:13 am
The researchers assume that the high rates near the Kinneret and on the Golan Heights owe to a shortage of specialists in respiratory medicine, which leads to high admissions following uncontrolled as... […]
- Digital Landscape, 2018: Asthma - ResearchAndMarkets.com on December 14, 2018 at 1:01 am
Digital Landscape: Asthma analyzes digital activities undertaken by pharma ... 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Pulmonary Medicine Copyright Business Wire 2018 […]
via Bing News